Neuroendocrine carcinoma of the stomach: A response to combination chemotherapy consisting of ramucirumab plus paclitaxel

Yuki Matsubara; Takayuki Ando; Ayumu Hosokawa; Hiroshi Mihara; Hiroaki Takagi; Naokatsu Nakata; Hiroki Yoshita; Sohachi Nanjo; Shinya Kajiura; Haruka Fujinami; Toshiro Sugiyama

doi:10.2169/internalmedicine.9369-17

Neuroendocrine carcinoma of the stomach: A response to combination chemotherapy consisting of ramucirumab plus paclitaxel

Yuki Matsubara, Takayuki Ando^*, Ayumu Hosokawa, Hiroshi Mihara, Hiroaki Takagi, Naokatsu Nakata, Hiroki Yoshita, Sohachi Nanjo, Shinya Kajiura, Haruka Fujinami, Toshiro Sugiyama

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

Extrapulmonary neuroendocrine carcinoma (NEC) is a rare disease, and there is no standard chemotherapy. A 73-year-old man was diagnosed with advanced gastric NEC. He received chemotherapy of irinotecan plus cisplatin, and amrubicin monotherapy. After failure of second-line chemotherapy, he received ramucirumab plus paclitaxel; this treatment was chosen because vascular endothelial growth factor 2 was strongly expressed in the tumor endothelial cells. After two cycles, his NEC had markedly reduced in size, and he continued with this treatment for over eight months. In this case, the combination of an anti-angiogenic inhibitor and a cytotoxic agent was highly effective for gastric NEC.

Original language	English
Pages (from-to)	671-675
Number of pages	5
Journal	Internal Medicine
Volume	57
Issue number	5
DOIs	https://doi.org/10.2169/internalmedicine.9369-17
State	Published - 2018

Keywords

Chemotherapy
Neuroendocrine carcinoma
Paclitaxel
Ramucirumab
VEGFR2

ASJC Scopus subject areas

Internal Medicine

Access to Document

10.2169/internalmedicine.9369-17

Cite this

@article{560998286f134910aea2478693d9743c,

title = "Neuroendocrine carcinoma of the stomach: A response to combination chemotherapy consisting of ramucirumab plus paclitaxel",

abstract = "Extrapulmonary neuroendocrine carcinoma (NEC) is a rare disease, and there is no standard chemotherapy. A 73-year-old man was diagnosed with advanced gastric NEC. He received chemotherapy of irinotecan plus cisplatin, and amrubicin monotherapy. After failure of second-line chemotherapy, he received ramucirumab plus paclitaxel; this treatment was chosen because vascular endothelial growth factor 2 was strongly expressed in the tumor endothelial cells. After two cycles, his NEC had markedly reduced in size, and he continued with this treatment for over eight months. In this case, the combination of an anti-angiogenic inhibitor and a cytotoxic agent was highly effective for gastric NEC.",

keywords = "Chemotherapy, Neuroendocrine carcinoma, Paclitaxel, Ramucirumab, VEGFR2",

author = "Yuki Matsubara and Takayuki Ando and Ayumu Hosokawa and Hiroshi Mihara and Hiroaki Takagi and Naokatsu Nakata and Hiroki Yoshita and Sohachi Nanjo and Shinya Kajiura and Haruka Fujinami and Toshiro Sugiyama",

note = "Publisher Copyright: {\textcopyright}2018 The Japanese Society of Internal Medicine.",

year = "2018",

doi = "10.2169/internalmedicine.9369-17",

language = "英語",

volume = "57",

pages = "671--675",

journal = "Internal Medicine",

issn = "0918-2918",

publisher = "Japanese Society of Internal Medicine",

number = "5",

}

TY - JOUR

T1 - Neuroendocrine carcinoma of the stomach

T2 - A response to combination chemotherapy consisting of ramucirumab plus paclitaxel

AU - Matsubara, Yuki

AU - Ando, Takayuki

AU - Hosokawa, Ayumu

AU - Mihara, Hiroshi

AU - Takagi, Hiroaki

AU - Nakata, Naokatsu

AU - Yoshita, Hiroki

AU - Nanjo, Sohachi

AU - Kajiura, Shinya

AU - Fujinami, Haruka

AU - Sugiyama, Toshiro

PY - 2018

Y1 - 2018

N2 - Extrapulmonary neuroendocrine carcinoma (NEC) is a rare disease, and there is no standard chemotherapy. A 73-year-old man was diagnosed with advanced gastric NEC. He received chemotherapy of irinotecan plus cisplatin, and amrubicin monotherapy. After failure of second-line chemotherapy, he received ramucirumab plus paclitaxel; this treatment was chosen because vascular endothelial growth factor 2 was strongly expressed in the tumor endothelial cells. After two cycles, his NEC had markedly reduced in size, and he continued with this treatment for over eight months. In this case, the combination of an anti-angiogenic inhibitor and a cytotoxic agent was highly effective for gastric NEC.

AB - Extrapulmonary neuroendocrine carcinoma (NEC) is a rare disease, and there is no standard chemotherapy. A 73-year-old man was diagnosed with advanced gastric NEC. He received chemotherapy of irinotecan plus cisplatin, and amrubicin monotherapy. After failure of second-line chemotherapy, he received ramucirumab plus paclitaxel; this treatment was chosen because vascular endothelial growth factor 2 was strongly expressed in the tumor endothelial cells. After two cycles, his NEC had markedly reduced in size, and he continued with this treatment for over eight months. In this case, the combination of an anti-angiogenic inhibitor and a cytotoxic agent was highly effective for gastric NEC.

KW - Chemotherapy

KW - Neuroendocrine carcinoma

KW - Paclitaxel

KW - Ramucirumab

KW - VEGFR2

UR - http://www.scopus.com/inward/record.url?scp=85042781524&partnerID=8YFLogxK

U2 - 10.2169/internalmedicine.9369-17

DO - 10.2169/internalmedicine.9369-17

M3 - 学術論文

C2 - 29151523

AN - SCOPUS:85042781524

SN - 0918-2918

VL - 57

SP - 671

EP - 675

JO - Internal Medicine

JF - Internal Medicine

IS - 5

ER -

Neuroendocrine carcinoma of the stomach: A response to combination chemotherapy consisting of ramucirumab plus paclitaxel

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Fingerprint

Cite this